BIO International Convention 2026
Date: 22-25 June
Location: San Diego, USA
Neogap Therapeutics will participate at the BIO International Convention as part of the European Innovation Council (EIC) Pavilion, within the EIC International Trade Fairs Programme. CEO Samuel Svensson and COO Andrea Salmén will represent Neogap as one of only 15 selected companies — and the only Swedish company — in the delegation. The participation highlights growing international interest in Neogap’s personalised immunotherapy pTTL, currently in Phase I/II clinical development for advanced colorectal cancer.
More information at BIO International Convention 2026.
International Neoantigen Summit 2026
Date: 21-23 July
Location: Amsterdam, The Netherlands
We’re excited to share that Luigi Notari, Senior Scientist of Neoantigen Production and Development, will be speaking at the 9th International Neoantigen Summit. Join us to explore our EpiTCer® technology and its application in the manufacturing of the investigational medicinal product pTTL, currently in clinical trials. We look forward to engaging conversations and inspiring scientific exchange!
More information at 9th International Neoantigen Summit 2026.
Previous events
Biotech Hanse Forum 2026
Date: 9 June
Location: Stockholm, Sweden
Neogap’s CEO, Samuel Svensson, will participate in and present at the upcoming Biotech Hanse Forum, hosted at Vinnova. During the event, he will provide an update on the company’s ongoing Phase Ib clinical trial in advanced colorectal cancer. We look forward to engaging in discussions on the future of personalised T-cell therapies and their potential to transform cancer treatment.
More information at Biotech Hanse Forum 2026.
Global Forum 2026
Date: 21 May
Location: Lund, Sweden
CEO Samuel Svensson will present Neogap’s personalised immunotherapy pTTL at BioStock’s Global Forum 2026 and share updates from the company’s ongoing Phase Ib clinical trial in advanced colorectal cancer — an area with significant unmet medical need and poor survival outcomes. We look forward to discussing the future of personalised T-cell therapies with investors, partners, and industry colleagues at the event.
More information at Global Forum 2026.
23rd CIMT Annual Meeting 2026
Date: 11-13 May
Location: Mainz, Germany
Our CSO & Founder, Hans Grönlund, and Senior Scientist, Vilma Urbonaviciute, will be attending the annual CIMT meeting to engage with the cancer immunotherapy community and discuss advances in personalised T-cell therapies. If you’re attending, we’d be glad to connect and share more about Neogap’s approach to personalised immunotherapy.
More information at 23rd CIMT Annual Meeting.
COG Nordics 2026
Date: 24-25 March
Location: Malmö, Sweden
Neogap’s CTO, Guro Gafvelin, will attend COG Nordics 2026 in Malmö. Representing Neogap, a clinical-stage biopharmaceutical company developing personalised immunotherapies, she will engage with peers on advancing innovative cancer treatments. With Neogap’s pTTL platform harnessing patients’ own immune cells to target tumour-specific neoantigens, discussions will focus on both the potential and challenges of next-generation cell therapies. We look forward to connecting and exchanging insights with collaborators across the clinical development ecosystem.
More information at COG Nordics 2026.
10th CCE Annual Meeting & Karolinska CCC Days 2026
Date: 23-24 March
Location: Stockholm, Sweden
Connect with Anne Laure Joly, Scientific Lead for Cell Therapy Development and Analyses at Neogap Therapeutics. During the meeting, Anne Laure will present her poster “A neoantigen targeted T cell therapy product for treatment of colorectal cancer”. Seize the opportunity to engage with her, learn more about Neogap’s cutting edge therapeutic advancements, and explore the future of personalised cancer treatment. Looking forward to inspiring discussions and new connections!
More information at 10th CCE Annual Meeting & Karolinska CCC Days 2026.
Biologics World Nordics 2026
Date: 18-19 March
Location: Stockholm, Sweden
Our COO, Andrea Salmén, will be speaking at Biologics World Nordics 2026 — a key gathering for leaders advancing biologics and next-generation therapies in the Nordic region. Drawing on Neogap’s work in personalised T-cell therapy and the ongoing clinical development of pTTL (personalised Tumour-Trained Lymphocytes), she will share insights from running a clinical-stage cell therapy programme. Her talk will focus on practical lessons in clinical operations and manufacturing, along with the challenges of bringing personalised immunotherapies into clinical use. We look forward to connecting, exchanging perspectives, and engaging in insightful discussions.
More information at Biologics World Nordics 2026.
J.P. Morgan Healthcare Week 2026
Date: 12-15 January
Location: San Francisco, USA
Neogap will attend J.P. Morgan Healthcare Week in San Francisco as part of the Business Sweden Sweden–US Life Science Program. Samuel Svensson (CEO), Andrea Salmén (COO), and Ola Nilsson (Head of Neoantigen Operations) will be on site to discuss our clinical progress, including our ongoing Phase I/IIa trial in metastatic colorectal cancer, and explore collaboration opportunities in personalised immunotherapy. Samuel Svensson will also present at the Swedish Breakfast on 12 January, highlighting Neogap’s tumour-targeted cell therapy approach. Get in touch to schedule a meeting — we look forward to connecting in San Francisco.
More information at J.P. Morgan Healthcare Week 2026.
ATMP Sweden 2025 Conference
Date: 27-28 November
Location: Gothenburg, Sweden
Meet Kristine Bylund (Head of Cell Therapy Production and Development) at the upcoming ATMP Sweden Conference. Don’t miss the chance to engage with her and explore Neogap’s pioneering therapeutic innovations. Looking forward to meaningful conversations and new connections!
More information at ATMP Sweden.
TIL Therapies Summit 2025
Date: 11-13 November
Location: Boston, USA
We are excited to share that Samuel Svensson, CEO, and Anne-Laure Joly, Scientific Lead Cell Therapy Development and Analyses at Neogap Therapeutics, will at the 7th TIL Therapies Summit in Boston, USA. Anne-Laure will co-chair the workshop ”Overcoming Scale-Up Challenges to Ensure Preparation for Commercial Scale”. Here she will also present pTTL (personalised Tumour-Trained Lymphocytes), focusing on the journey from academia, to the ongoing Phase I/IIa clinical trial, and finally the preparation for the next trial. ”It is a real opportunity to connect, share our approach to personalised immunotherapy, and gain valuable insights from the latest developments in the field”, says Anne-Laure.
More information at TIL Therapies Summit.
13th Annual Outsourcing in Clinical Trials Nordics 2025
Date: 21-22 October
Location: Copenhagen, Denmark
During this meeting, our COO Andrea Salmén will be sharing challenges and best practice in cell therapy trials from a small biotech perspective. Take the chance to discuss our personalised approach and learnings from our ongoing clinical trial with Andrea.
More information at Annual Outsourcing in Clinical Trials Nordics 2025
European Society for Medical Oncology (ESMO) Congress 2025
Date: 17-21 October
Location: Berlin, Germany
Meet Maximilian Kordes, Principal Investigator of Neogap’s ongoing first-in-human clinical trial, at ESMO Congress 2025. He will present the latest trial progress and share valuable insights from the study. Don’t miss this opportunity to engage in discussion and learn more about our groundbreaking work.
More information at ESMO congress 2025.
Annual Workshop of the Center for Cellular Cancer Therapy (C3T)
Date: 4-5 September
Location: Stockholm, Sweden
Connect with Hans Grönlund, Founder and CSO of Neogap Therapeutics, at the 2nd Annual Workshop of the Center for Cellular Cancer Therapy (C3T). Hans will give a presentation highlighting our cutting-edge cancer therapies. Don’t miss the chance to discuss our innovative technologies firsthand and explore how we are shaping the future of cancer treatment.
More information at Annual C3T Workshop.
Advanced Therapies Europe 2025
Date: 2-4 September
Location: Barcelona, Spain
We are proud to announce that Neogap has been selected as one of six finalists to present at the Innovation Exchange during the upcoming Advanced Therapies Europe conference in Barcelona!
This is a great recognition of the innovative concept behind our work – and the urgent need for novel, personalised cancer therapies like ours. We are looking forward to sharing our progress, connecting with global leaders in advanced therapies, and continuing to push the boundaries of what is possible in cell therapy.
More information at Advanced Therapies Europe.
International Neoantigen Summit 2025
Date: 24-26 June
Location: Amsterdam, Netherlands
We are delighted to share that Ola Nilsson, Head of Neoantigen Production, Development & Clinical Processing at Neogap Therapeutics, will present pTTL (personalised Tumour-Trained Lymphocytes) at the 8th International Neoantigen Summit 2025. His presentation will focus on Neogap’s ongoing first-in-human trial for stage IV colorectal cancer, highlighting how pTTL uses autologous T cells from regional lymph nodes to target patient-specific neoantigens, offering a novel approach in adoptive T cell therapy.
More information at International Neoantigen Summit.
EIC Soft-landing Programme 2025
Date: 9-13 June
Location: Boston, USA
During the EIC Soft-landing Programme for Healthcare and Life Sciences in Boston, Samuel Svensson, CEO of Neogap Therapeutics, will showcase our technology to investors and potential partners and join networking sessions. ”Being selected for the EIC Soft-landing Programme is a strong validation of the relevance of our technology in a global innovation context. This programme offers us a concrete opportunity to strengthen our presence in the US market and build new relationships,” says Samuel Svensson.
More information at Neogap news.
SACCNY Innovate Nordics 2025 – Grand Pitch Finale
Date: 19-21 May
Location: New York, USA
Our COO Andrea Salmén will represent Neogap during the Innovate Nordics 2025 Acceleration Program in New York, hosted by Swedish-American Chamber of Commerce – New York (SACCNY) and EY. Andrea will participate in the Grand Pitch Finale, meet with investors, explore new partnerships, and present Neogap’s approach to personalised cancer immunotherapy. We are proud to be among the selected Nordic companies joining the programme and excited to connect with the broader life science community in New York.
EDIT: Andrea won the Grand Pitch Finale!!!
More information at SACCNY Innovate Nordics.
CIMT Annual Meeting 2025
Date: 12-14 May
Location: Mainz, Germany
We are pleased to announce our participation in the 22nd CIMT Annual Meeting. Hans Grönlund, founder and CSO of Neogap Therapeutics, will present a poster highlighting our groundbreaking technologies. Take this opportunity to engage with Hans and delve into our pioneering therapeutic approaches.
More information at CIMT Annual Meeting.
SACCNY Innovate Nordics 2025 – Kick-off
Date: 8 May
Location: Stockholm, Sweden
We are proud to take part in The Nordic Pitch in Stockholm, hosted by the Swedish-American Chamber of Commerce – New York (SACCNY) and EY as part of the Innovate Nordics Acceleration Program. Our COO, Andrea Salmén, will pitch Neogap and share our vision for the future of personalised immunotherapy – using precision-selected neoantigens to develop next-generation T-cell therapies. The event brings together leading voices in health innovation and Nordic capital markets. We look forward to sharing our progress and connecting with others who share our ambition to transform cancer treatment.
More information at SACCNY Innovate Nordics.
Nordic Precision Medicine Forum 2025
Date: 28-29 April
Location: Stockholm, Sweden
Meet Hans Grönlund, founder and CSO of Neogap Therapeutics, for a personal discussion on our cutting-edge therapeutic technologies at the Nordic Precision Medicine Forum 2025.
More information at Nordic Precision Medicine Forum.
KI Innovations InvestorDay 2025
Date: 10 April
Location: Solna, Sweden
We invite you to KI Innovations InvestorDay 2025 to engage with Hans Grönlund, founder and CSO of Neogap Therapeutics, and explore our innovative therapeutic approach and potential opportunities.
More information at KI Innovations InvestorDay.
Swiss Nordic Bio 2025
Date: 13 March
Location: Zurich, Switzerland
We are thrilled to announce our participation in Swiss Nordic Bio, a premier event connecting biotech, pharmaceutical, and healthtech companies with top investors and industry leaders. This exclusive opportunity allows us to showcase our innovative therapy, engage in face-to-face meetings with potential investors and partners. We look forward to forging valuable connections and exploring new avenues for collaboration in the dynamic healthcare landscape.
More information at Swiss Nordic Bio.
Biologics World Nordics 2025
Date: 5-6 March
Location: Stockholm, Sweden
Guro Gafvelin, the CTO at Neogap Therapeutics, will deliver a presentation on personalised T-cell therapies for cancer at Biologics World Nordics 2025. Her talk will highlight our innovative cell therapy approach, showcasing our commitment to advancing cancer treatment. We invite you to engage with Guro, as well as her colleagues Andrea Salmén, COO, and Kristine Bylund, Head of Cell Therapy Production and Development, during the event to discuss our cutting-edge cancer therapy and explore potential investment opportunities and partnership possibilities.
More information at Biologics World Nordics 2025.
ATMP Sweden 2024 Conference
Date: 25-26 November
Location: Malmö, Sweden
Neogap will participate in the annual ATMP Sweden conference in Malmö, where we will engage with peers to discuss advancements in therapeutics. We are excited to present our latest developments in the poster titled “A first in human Phase I/IIa trial of personalised Tumour-Trained Lymphocytes, pTTL, derived from regional lymph nodes for treatment of colorectal cancer”.
More information at ATMP Sweden.
SITC 2024
Date: 6-10 November
Location: Houston, USA
We will be at the Society for Immunotherapy of Cancer (SITC) Conference to showcase our poster “Personalized Tumor-Trained Lymphocytes – A neoantigen targeted T cell therapy product for treatment of colorectal cancer”.
Guro Gafvelin, our CTO, and Sofia Berglund, Principal Scientist Clinical Development, will be there to connect and discuss deeper insights.
More information at SITC 2024.
BIO-Europe 2024
Date: 4-6 November
Location: Stockholm, Sweden
Andrea Salmén, COO, and Ola Nilsson, Head of Neoantigen Production & Development, will be there to discuss advances in immuno-oncology and explore partnerships for our innovative cell therapy program.
More information at BIO-Europe.